3D Cell Culture Market Growth, and Regional Insights
The global 3D cell culture market was valued at $2.10 billion in 2023 and is expected to reach $7.02 billion by 2034, growing at a compound annual growth rate (CAGR) of 11.6% from 2024 to 2034. This growth is primarily driven by increasing research and advancements in spheroids and organoids.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5201
Key Insights of the 3D Cell Culture Market
- Regional Insights: North America held the largest share of the 3D cell culture market, accounting for 42.01% in 2023. However, the Asia Pacific region is expected to experience the fastest growth during the forecast period.
- Technology Trends: The scaffold-based technology segment led the market in 2023. Meanwhile, the scaffold-free segment is anticipated to grow at the fastest rate over the forecast period.
- Application Insights: The stem cell research and tissue engineering segment dominated the market in 2023. The cancer research segment is expected to grow the fastest during the forecast period.
- End-Use Insights: Biopharmaceutical and pharmaceutical companies held the largest share of the 3D cell culture market in 2023. However, academic and research institutes are projected to see the fastest growth during the forecast period.
Recent Announcements from Industry Leaders
Eric Perreault has been appointed as the new CEO of Kiyatec, Inc., a biotechnology company specializing in 3D cell culture technology. He aims to lead the company in transforming cancer care, particularly for brain cancer patients, by leveraging 3D cell culture technology to enhance patient outcomes.
Recent Developments in the 3D Cell Culture Market
- In August 2024, Cell Microsystems, a leader in innovative cell biology instruments, expanded its contract research lab services. Utilizing their advanced CellRaft® Technology, the services now include generating cell lines, custom organoids, and conducting various tests.
- In June 2024, Predictive Oncology, a company focused on biologics and drug discovery, introduced a new 3D cell culture model to accelerate cancer treatment development. The company has developed in vitro organ and disease-specific models that accurately replicate human tissue’s physiological conditions.
- In June 2023, ioFibR, a tissue engineering innovator based in Halifax, Nova Scotia, launched two new collagen fiber products: CollaFibRTM 3D scaffold and μCollaFibRTM (micro-CollaFibRTM). These products, created using ioFibR’s unique dry-spinning technique, offer significant advantages for tissue engineering and culture applications.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/3d-cell-culture-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5201
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
